Lucid Diagnostics priced an underwritten registered direct offering of 18 million shares at $1.00 per share, raising expected gross proceeds of $18 million. The financing is anchored by a $15 million investment from a fundamental institutional investor with support from an existing large shareholder. Lucid said it plans to use the proceeds for working capital and general corporate purposes, with the offering expected to close April 24. The company markets EsoGuard, an esophageal DNA test for patients with GERD symptoms at risk for esophageal cancer. For the diagnostics sector, the transaction reflects how clinical evidence, reimbursement progress, and operational scaling plans can quickly draw on equity financing even when product demand exists.